Monoclonal Antibody Prevents Malaria in Small NIH Trial Reported in New England Journal of Medicine

One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people. The trial was sponsored and conducted by scientists from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and was funded by the NIAID. The findings were published online on August 11,2021 in the New England Journal of Medicine. The article is titled “A Monoclonal Antibody for Malaria Prevention.”